Cell–cell junction gene signatures as subtype-specific prognostic biomarkers in breast cancer
PLOS One · 29.06.2026 · 21 (6) · e0352254
DOI: 10.1371/journal.pone.0352254 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 29.06.2026. Verfasst von Hayato Ishii und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Intercellular Junctions. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Tokyo University of Science Grant for President’s Research Promotion, Moonshot Research and Development Program, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Cell–cell junctions (CCJs) are essential for maintaining epithelial integrity, and adhesion-related molecules have long been implicated in breast cancer progression. However, the subtype-specific prognostic significance of CCJ-related gene expression patterns within individual intrinsic breast cancer subtypes has not been systematically characterized. We analyzed 179 genes annotated to the Gene Ontology term “cell–cell junction organization” (GO:0045216) across intrinsic breast cancer subtypes using the METABRIC and The Cancer Genome Atlas (TCGA) datasets. Subtype-specific prognostic CCJ genes were identified using multivariate Cox proportional hazards models for disease-specific survival and integrated into CCJ gene expression signatures. The prognostic performance was validated in an independent cohort (SCAN-B). Elevated CCJ signature scores were associated with poorer survival across subtypes, with particularly strong effects in Luminal B (LumB) and Basal-like (Basal) tumors. Person-year analyses indicated that high CCJ scores predicted an increased incidence of early recurrence (0–5 years) in these aggressive subtypes. Pathway enrichment analyses revealed that high-score tumors exhibited upregulation of extracellular matrix organization and matrisome-related pathways. Single-cell RNA sequencing further demonstrated that LumB CCJ genes (e.g., PARD6B , CDH3 ) were predominantly expressed in tumor epithelial cells, whereas the Basal CCJ signature reflected contributions from epithelial (e.g., MARVELD2 ) and endothelial (e.g., RAMP2 ) cells. Collectively, CCJ signatures stratify prognosis and capture subtype-specific cellular and microenvironmental features in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.
- Research Division of Medical Data Science, Research Institute for Science and Technology, Tokyo University of Science, Chiba, Japan.
- Laboratory of Cancer Biology, Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan.
ORCID-Profile: Shoma Tamori, Kazunori Akimoto
Förderung
- the Tokyo University of Science Grant for President’s Research Promotion
- Moonshot Research and Development Program
- Japan Society for the Promotion of Science
- Grant-in-Aid for Early-Career Scientists
- a grant from the Institute for Environmental & Gender-Specific Medicine
Zitieren
APA
Ishii, H., Nishiyama, K., Nakahara, A., Tamori, S., Ohno, S., Sasaki, K., & Akimoto, K. (2026). Cell–cell junction gene signatures as subtype-specific prognostic biomarkers in breast cancer. PLOS One, 21(6), e0352254. https://doi.org/10.1371/journal.pone.0352254
Vancouver
Ishii H, Nishiyama K, Nakahara A, Tamori S, Ohno S, Sasaki K, et al. Cell–cell junction gene signatures as subtype-specific prognostic biomarkers in breast cancer. PLOS One. 2026;21(6):e0352254. doi:10.1371/journal.pone.0352254
BibTeX
@article{Ishii2026,
author = {Ishii, Hayato and Nishiyama, Kyoka and Nakahara, Ayaka and Tamori, Shoma and Ohno, Shigeo and Sasaki, Kazunori and Akimoto, Kazunori},
title = {Cell–cell junction gene signatures as subtype-specific prognostic biomarkers in breast cancer},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {6},
pages = {e0352254},
doi = {10.1371/journal.pone.0352254}
}
EUVIMED